文献速递毛发、甲与色素性疾病

托法替尼治疗白癜风复色可能需联合光照暴露

Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
PubMed 文献 · J Am Acad Dermatol · 2017-08-18

该回顾性病例系列评估JAK1/3抑制剂托法替尼治疗10例连续白癜风患者的疗效,以脱色素体表面积评估病情。5例在日光暴露或低剂量窄谱中波紫外线光疗部位获得部分复色;吸疱采样显示治疗期间应答与非应答皮损的自身免疫反应均受抑制,提示光照而非免疫抑制是黑素细胞再生所必需。结论认为JAK抑制剂治疗白癜风似需光照暴露,低水平光照即可能足够,复色维持或可单用JAK抑制剂。

要点

  • 托法替尼治疗10例白癜风患者中5例在光照暴露部位出现部分复色。
  • 吸疱采样示应答与非应答皮损的自身免疫反应均受抑制,提示光照对黑素细胞再生关键。
  • JAK抑制剂治疗白癜风可能仅需低水平光照,复色维持或可单药。

核心结论

  • JAK抑制剂治疗白癜风似需联合光照暴露,低水平光照即可能足够,复色维持或可单用JAK抑制剂。

研究设计与样本

  • 回顾性病例系列,纳入10例连续白癜风患者,接受托法替尼治疗,以脱色素体表面积评估病情严重度。

主要发现

  • 10例中5例在日光暴露或低剂量窄谱中波紫外线光疗部位获得部分复色。
  • 吸疱采样显示治疗期间应答与非应答皮损的自身免疫反应均受抑制。

关键数值与推荐

  • 5例获得部分复色的患者其复色部位为日光暴露或低剂量窄谱中波紫外线光疗区域。

临床怎么用

  • 对接受JAK抑制剂治疗的白癜风患者,可考虑联合日光暴露或低剂量窄谱中波紫外线光疗以促进复色。

局限性

  • 研究样本量小、为回顾性设计且缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. OBJECTIVE: To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. METHOD: This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation. RESULTS: Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low-dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration. LIMITATIONS: Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group. CONCLUSION: Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017. PMID: 28823882. doi:10.1016/j.jaad.2017.05.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。